Camurus AB (0RD1)
London Exchange · UK · prices in SEK · close of 20 Oct 2026
Key indicators
| Last close | SEK 665.50 |
|---|---|
| 52-week range | 433.00 – 707.50 |
| Return, 1 month / 3 months | +7.6% / +8.2% |
| Return, 1 year / 3 years | +7.3% / +107.4% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 44.4% |
| Worst drawdown (1 year) | -37.7% |
| Average daily value traded | 7.39M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Camurus AB is a pharmaceutical company based in Lund, Sweden, that develops and commercialises medicines formulated to release their active ingredients slowly over time. Its products are long-acting injectable and implantable treatments built on the company's lipid-based delivery technology, and they are used in areas such as the treatment of opioid dependence and the management of pain and other chronic conditions. The company works with healthcare providers and partners to make these treatments available in markets around the world.
The shares are listed on the London Exchange in UK under the code 0RD1, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Camurus AB (0RD1) trades on the London Exchange in UK. It last closed at SEK 665.50 on 20 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 1,161 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.3% and over the last three months it rose 8.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.3% | ||
| From 52-week high | -5.2% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.2% | ||
| 6-month return | 23.1% | ||
| 12-month return, skipping the last month | -0.3% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 44.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.7% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 7.39M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +5.1% |
|---|---|
| 1 month | +7.6% |
| 3 months | +8.2% |
| 6 months | +23.1% |
| 1 year | +7.3% |
| 3 years | +107.4% |
| 5 years | – |
Signals
| 50-day / 200-day average | 616.15 / 572.10 |
|---|---|
| Golden / death cross (60 days) | Golden, 51 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 14.86 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.